PMID- 20676961
OWN - NLM
STAT- MEDLINE
DCOM- 20101122
LR  - 20211020
IS  - 1615-2573 (Electronic)
IS  - 0910-8327 (Linking)
VI  - 25
IP  - 5
DP  - 2010 Sep
TI  - Short-term effect of levosimendan on free light chain kappa and lambda levels in 
      patients with decompensated chronic heart failure.
PG  - 392-9
LID - 10.1007/s00380-009-1216-4 [doi]
AB  - To investigate the effects of levosimendan, a positive inotropic agent, on the 
      new heart failure markers immunoglobulin free light chains kappa and lambda 
      (FLC-kappa and FLC-lambda) in decompensated chronic heart failure (HF), 59 
      patients with New York Heart Association (NYHA) class III-IV HF were enrolled. 
      Patients were randomized into levosimendan (n = 31) and standard HF treatment (n 
      = 29) groups. Serum FLC-kappa and FLC-lambda, brain natriuretic peptide (BNP), 
      and ejection fraction (EF) were measured before treatment and on the 5th day of 
      treatment initiation. Forty-two percent of subjects were females (n = 25) and 
      overall mean age was 64.1 +/- 10.7 years. FLC-kappa (P < 0.05) and FLC-lambda (P 
      < 0.05) were significantly decreased in the levosimendan group compared to 
      baseline, but no difference in either marker in the standard treatment group was 
      observed. Pre- and post-treatment FLC-kappa/FLC-lambda ratios in both groups were 
      similar, whereas FLC-kappa and FLC-lambda levels and the FLC-kappa/FLC-lambda 
      ratio showed no significant correlation with NYHA class, brain natriuretic 
      peptide (BNP) and ejection fraction (EF) levels; and BNP and EF changes after the 
      treatment. Symptomatic improvement in the levosimendan group according to the 
      NYHA class was significantly better than in the standard treatment group (P = 
      0.044). While 55.2% of patients in the levosimendan group showed a 1-degree shift 
      to lower NYHA classes, 10.3% showed a 2-degree decrease. In conclusion, 
      levosimendan caused short-term hemodynamic and symptomatic improvements, with a 
      more pronounced decrease in FLC levels in patients with advanced decompensated 
      HF.
FAU - Kurt, Ibrahim Halil
AU  - Kurt IH
AD  - Department of Cardiology, Adana Numune Teaching and Research Hospital, Turkey. 
      ibrahimhalilkurt@gmail.com
FAU - Yavuzer, Kemal
AU  - Yavuzer K
FAU - Batur, Mustafa Kemal
AU  - Batur MK
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20100731
PL  - Japan
TA  - Heart Vessels
JT  - Heart and vessels
JID - 8511258
RN  - 0 (Biomarkers)
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Hydrazones)
RN  - 0 (Immunoglobulin kappa-Chains)
RN  - 0 (Immunoglobulin lambda-Chains)
RN  - 0 (Pyridazines)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 349552KRHK (Simendan)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers/blood
MH  - Cardiotonic Agents/*therapeutic use
MH  - Chronic Disease
MH  - Down-Regulation
MH  - Female
MH  - Heart Failure/*drug therapy/immunology/physiopathology
MH  - Humans
MH  - Hydrazones/*therapeutic use
MH  - Immunoglobulin kappa-Chains/*blood
MH  - Immunoglobulin lambda-Chains/*blood
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood
MH  - Pyridazines/*therapeutic use
MH  - Severity of Illness Index
MH  - Simendan
MH  - Stroke Volume/drug effects
MH  - Time Factors
MH  - Treatment Outcome
MH  - Turkey
EDAT- 2010/08/03 06:00
MHDA- 2010/12/14 06:00
CRDT- 2010/08/03 06:00
PHST- 2009/06/16 00:00 [received]
PHST- 2009/10/23 00:00 [accepted]
PHST- 2010/08/03 06:00 [entrez]
PHST- 2010/08/03 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
AID - 10.1007/s00380-009-1216-4 [doi]
PST - ppublish
SO  - Heart Vessels. 2010 Sep;25(5):392-9. doi: 10.1007/s00380-009-1216-4. Epub 2010 
      Jul 31.